Case Report

Clinical pathology aspect on diagnosis cholelithiasis in β-Thalassemia patient: A case report

Muhammad Bintang Maulana a, Muhamad Robi’ul Fuadi b, *

a Study Program of Clinical Pathology, Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
b Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

ARTICLE INFO

Keywords:
Abdominal ultrasound
β-Thalassemia
Cholelithiasis

ABSTRACT

Background: Thalassemia is categorized based on the abnormal globin chain and is divided into primary, intermediate, and minor subtypes based on the chain abnormality, respectively.
Case presentation: An Indonesian adolescent, 18 years old, complained of abdominal pain for 1-day. Medical history patient showed thalassemia for 13 years, routine control and received transfusions. Physical examination: Anemic conjunctiva (+/−), epigastric tenderness (+). Laboratory tests: Hb of 4.2 g/dL, MCV of 59.8 fl, and MCH of 19.6 pg. Peripheral blood smears showed microcytic hypochromic, target cells, and teardrop cells. Increased albumin: creatinine ratio ≥300 mg/gr. Hb Electrophoresis showed increased HbF and HbA2 fractions. Abdominal Ultrasound showed cholelithiasis. The patient performed laparoscopic cholecystectomy and was successful.

Discussion: Cholelithiasis is often found in thalassemia intermedia complications. Regular ultrasound examination in β-Thalassemia is used to detect cholelithiasis. Clinical pathology analysis supports the diagnosis of cholelithiasis in the β-Thalassemia patient.

Conclusion: Clinical pathology analysis supports the diagnosis of cholelithiasis in the β-Thalassemia patient.

1. Introduction

Thalassemia is a heterogeneous grouping of genetic disorders that result from a decreased synthesis of alpha or beta chains of hemoglobin (Hb) [1,2]. It was reported that the number of cases of thalassemia was 4.4 : 10,000 live births [3]. Complications of thalassemia included hematomegaly, splenomegaly, pulmonary hypertension, and anemia due to ineffective hemolysis and erythrophagocytosis [4]. One of the most common complications in thalassemia cases is cholelithiasis which is reported in 10–57% of thalassemia patients [5]. The aimed to report an Indonesian adolescent with β-thalassemia and cholelithiasis. We report based on SCARE 2020 guidelines [6].

2. Case presentation

An Indonesian adolescent, 18 years old, complained of abdominal pain for 1-day, intermittent pain, can’t defecate for 7 days, can’t fast, and low intake of food. The patient consumed microleak but couldn’t defecate. Medical history showed the patient was diagnosed with thalassemia 13 years ago and had routine medical checkups and transfusions. Physical examination showed pale conjunctiva (+/−), splenomegaly, and abdominal tenderness. Hematology laboratory investigation showed Hb (4.2 g/dL), RBC (2.14 × 106/μL), Hct (12.8%), MCV (59.8 fl), MCH (19.6 pg), and MCHC (32.8 g/L). Peripheral blood smear examination revealed hypochromic macrocytic anemia, anisopoikilocytosis, and leukocytosis with immature granulocytes (Fig. 1).

The patient also underwent a clinical chemical laboratory investigation, which showed BUN of 5 mg/dL, AST of 67 IU/L, ALT of IU/L, Na of 135 mmol/L, Direct bilirubin of 0.35 mg/dL, and triglyceride of 211 mg/dL. Urinalysis laboratory showed protein (+1), bilirubin (+1), albumin/creatinine (>300 mg/GCR), and protein/creatinine (0.3 g/GCR). The hemoglobin electrophoresis results showed a decrease in the HbA fraction and an increase in the HbF, HbG, and HbA2 fractions (Fig. 2). Radiological examination showed abdominal X-ray showed splenomegaly, and abdominal Ultrasound showed cholelithiasis with sludge in bile.

The patient performed laparoscopic cholecystectomy and was successful. The patient and family are recommended to do a blood examination once a month or if the patient has signs of anemia such as paleness when outpatient. If Hb shows a decrease, PRC will be carried out.

* Corresponding author. Department of Clinical Pathology, Faculty of Medicine, Airlangga University – Dr. Soetomo General Academic Hospital, Jl. Mayjend Prof. Dr. Moestopo No. 6-8, Airlangga, Gubeng, Surabaya, East Java, 60286, Indonesia.
E-mail address: muhamad-r-u-f@fk.unair.ac.id (M.R. Fuadi).

https://doi.org/10.1016/j.amsu.2022.104454
Received 24 June 2022; Received in revised form 13 August 2022; Accepted 13 August 2022
Available online 24 August 2022
2049-0801/© 2022 The Authors. Published by Elsevier Ltd on behalf of LJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The mechanism of anemia in patients with \( \beta \)-thalassemia occurs due to the loss of beta chains and excess alpha chains that make them unstable and precipitate, causing damage to red blood cell membranes. In addition, anemia in \( \beta \)-thalassemia patients is due to the short erythrocyte life span due to hemolysis and premature death of erythroid precursors in the bone marrow [7,8]. No treatment can cure thalassemia intermedia. Blood transfusion every 2–4 weeks is the only therapy for anemia in thalassemia patients. This continuous transfusion can result in iron overload in many organs, such as the heart, liver, kidneys, endocrine organs and others. The accumulation of free iron (ferrous iron/Fe\( ^{2+} \)) can cause a Fenton reaction that forms free radicals, causing oxidative stress, which will oxidize cell lipid membranes (lipid peroxidation) and nucleic acid modification, causing cell death, tissue damage and ultimately organ damage [9–11].

Complications of cholelithiasis are more common in thalassemia intermedia than in thalassemia major due to the ineffectiveness of erythropoiesis and the occurrence of peripheral hemolysis [4,12,13]. Gallstones in hemolytic anemia are often referred to as stones with black pigment. The content of the black pigment is a cross-linked network polymer bilirubin. Moreover, about 40–80% have a radiopaque appearance. Approximately 55–63% of patients with thalassemia intermedia suffer from gallstones. In patients with \( \beta \)-thalassemia, an ultrasound examination should be performed to detect gallstones [5,14,15].

The prevalence of cholelithiasis is higher in thalassemia intermedia compared to thalassemia major. Bilirubin production is increased due to the destruction of red blood cells during blood transfusion and partly because of ineffective erythropoiesis. The high transfusion regimen can prevent residual ineffective erythropoiesis resulting in decreased bilirubin production. Ineffective erythropoiesis and peripheral hemolysis, resulting in increased bilirubin production, are why the prevalence of cholelithiasis is higher in thalassemia intermedia compared to primary thalassemia patients [4,5,16].

The limitation of the case is the lack of a complete iron profile examination which includes ferritin and Prussian blue bone marrow aspirants staining [2].

4. Conclusion

Complications of cholelithiasis are more common in thalassemia intermedia than in thalassemia major. In patients with \( \beta \)-thalassemia, an ultrasound examination should be performed to detect the presence of gallstones. Urinalysis examination is critical to determine the complications of albuminuria in thalassemia patients. When outpatient, the patient and family are recommended to do a blood examination once a month or if the patient has signs of anemia such as paleness.

Ethical approval

Not applicable.

Sources of funding

None.

Fig. 1. The microscopic picture of 1000× magnification of the patient’s peripheral blood smear showed an image of erythrocytes with the formation of target cells and teardrop cells.

Fig. 2. Hemoglobin electrophoresis showed decreased Hb A fraction, increased Hb F, Hb E and Hb A2 fractions.
Author contribution
All authors contributed toward data analysis, drafting and revising the
paper, gave final approval of the version to be published and agree to
be accountable for all aspects of the work.

Trial registry number
1. Name of the registry:-.
2. Unique Identifying number or registration ID:-.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked):-.

Guarantor
Muhammad Robi’ul Fuadi is the person in charge of the publication of our manuscript.

Consent
Written informed consent was obtained from the patient’s parent or guardian for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Provenance and peer review
Not commissioned, externally peer-reviewed.

Declaration of competing interest
Muhammad Bintang Maulana and Muhammad Robi’ul Fuadi declare that they have no conflict of interest.

Acknowledgement
We would like to thank our editor, “Fis Citra Ariyanto”.

References
[1] A. d’Angom, M. G Putri, Y. Savitri, A.M.R. Alfaidin, Vitamin and Mineral Supplementation for β-thalassemia during COVID-19 Pandemic, vol. 6, 2020, p. FS0628, https://doi.org/10.2144/fsoa-2020-0110 (9).

[2] L. Goretti, C.O. Adiatmaja, H. Kahar, Severe microcytosis in a hemoglobin E/β-
thalassemia patient with signs of iron deficiency: a case report, Ann. Med. Surg. 78 (2022), 103826, https://doi.org/10.1016/j.amsu.2022.103826.

[3] K.A. Kadhim, K.H. Baldawi, F.H. Lami, Prevalence, incidence, trend, and complications of thalassaemia in Iraq, Hemoglobin 41 (3) (2017) 164–168, https://doi.org/10.1080/03630269.2017.1354877.

[4] M. Khavari, A. Hamidi, S. Haghpanah, M.H. Bagheri, M. Bardestani, R. Hantooshzadeh, et al., Frequency of cholelithiasis in patients with Beta-thalassaemia intermedia with and without hydroxyurea, Iran. Red Crescent Med. J. 16 (7) (2014), e18712, https://doi.org/10.5812/rcmj.18712.

[5] I. Shabramian, R. Behradmehr, M. Afkari, A. Allahdadi, M. Delaramnasab, A. Bazi, Cholelithiasis in thalassaemia major patients: a report from the South-East of Iran, Int. J. Hematol. Oncol. Stem Cell Res. 12 (2) (2018) 117–122.

[6] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, A. Kerwan, The SCARE 2020 guideline: updating consensus surgical Case REport (SCARE) guidelines, Int. J. Surg. 84 (2020) 226–230, https://doi.org/10.1016/j.ijsu.2020.10.034.

[7] B.C. Suharjo, B. Putut, R. Neneng, N. Siti, Gallstones and cholelitholysis with severe cholestatic jaundice in beta-thalassemia intermedia patient, Indones. J. Gastroenterol. Hepatol. Dig. Endosc. 15 (2) (2014) 120–124, https://doi.org/10.24871/1522014120-124.

[8] I. Kyriakidis, M. Palabougouki, E. Vasileiou, A. Tragiannidis, M. Stamou, M. Lotfi, P. Keramati, R. Assdsangabi, S.A. Nabavizadeh, M. Karimi, et al., Analysis of deferasirox and tocopherol as antioxidant on malondialdehyde level in pediatric patients with beta-thalassemia major, Folia Medica Indones. 53 (1) (2017) 49–55, https://doi.org/10.20473/fmi.v53i1.5490.

[9] L. Rismayanti, Y. Yulistiani, M.R. Andarsini, M. Qibtiyah, Analysis of DL-alpha-Tocopherol as antioxidant on malondialdehyde level in pediatric patients with hemoglobinopathy, Turk pediatric arsivi 54 (2) (2019) 129–132, https://doi.org/10.14744/TurkPediatriArs.2019.67674.

[10] F.T. Shah, F. Sayani, S. Trompeter, E. Drasar, A. Piga, Challenges of blood transfusions in β-thalassemia, Blood Rev. 37 (2019), 100588, https://doi.org/10.1016/j.bjredir.2019.100588.

[11] A. Lal, T. Wong, S. Keel, M. Pagano, J. Chung, A. Kandar, et al., The transfusion management of beta thalassemia in the United States, Transfusion 61 (10) (2021) 3027–3039, https://doi.org/10.1111/trf.16640.

[12] E.S. Sutrisaningsih, S. Suharjo, B. Sudarmanto, Analysis of deferiprone and deferipron use in children with pediatric beta-thalassemia mayor, Folia Medica Indones. 52 (1) (2017) 42–46, https://doi.org/10.20473/fmi.v52i1.5207.

[13] C. Asadov, Z. Alimirzoeva, T. Mammadova, G. Aliyeva, S. Gafarova, J. Mammadov, β-Thalassemia intermedia: a comprehensive overview and novel approaches, Int. J. Hematol. 108 (1) (2018) 5–21, https://doi.org/10.1007/s12185-018-2411-9.

[14] M. Lotfi, P. Keramati, R. Assdsangabi, S.A. Nabavizadeh, M. Karimi, Ultrasonographic assessment of the prevalence of cholelithiasis and biliary sludge in beta-thalassemia patients in Iran, Med. Sci. Mon. Int. Med. J. Exp. Clin. Res.: Int. Med. J. Exp. Clin. Res. 15 (8) (2009) Cr398–402.

[15] S.S. Amin, S.D. Jalal, K.M. Ali, A.J. Mohammed, L.K. Rassol, T.J. Osman, Beta-thalassemia intermedia: a single thalassemia center experience from Northeastern Iraq, BioMed Res. Int. 2020 (2020), 2807120, https://doi.org/10.1155/2020/2807120.

[16] J.A. Ribeil, J.B. Arlet, M. Dusejot, I.C. Moura, O. Hermine, Ineffective erythropoiesis in β-thalassemia, TheScientificWorldJOURNAL 2013 (2013), 394295, https://doi.org/10.1155/2013/394295.